摘要
目的探讨保妇康栓联合重组人干扰素α-2b治疗慢性宫颈炎并高危型人乳头瘤病毒(HPV)感染的临床疗效。方法选取抚州市第六医院2017年5月—2020年4月收治的慢性宫颈炎并高危型HPV感染患者60例,按照随机抽签法分为对照组与观察组,各30例。对照组予以重组人干扰素α-2b治疗,观察组在对照组治疗基础上应用保妇康栓治疗。比较2组临床疗效,HPV转阴率,治疗前后T淋巴细胞免疫功能指标(CD_(4)^(+)、细胞分数、CD_(8)^(+)、细胞分数、CD_(4)^(+)/CD_(8)^(+)细胞比值),并观察2组不良反应发生情况。结果观察组治疗总有效率高于对照组、HPV转阴率高于对照组(P<0.05)。治疗后,观察组CD_(4)^(+)细胞分数、CD_(8)^(+)细胞分数、CD_(4)^(+)/CD_(8)^(+)细胞比值高于对照组(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论保妇康栓α重组人干扰素α-2b治疗慢性宫颈炎并高危型HPV感染的临床疗效确切,可有效提高患者HPV转阴率和免疫功能,且安全性较高。
Objective To study the clinical efficacy of baofukang suppository combined with recombinant human interferon α-2 b in the treatment of chronic cervicitis complicated with high-risk HPV infection.Methods A total of 60 cases of patients with chronic cervicitis complicated with high-risk HPV infection were selected from May 2017 to April 2020 in the Sixth Hospital of Fuzhou,which were randomly divided into control group and observation group,30 cases in each group.The control group was treated with recombinant human interferon α-2 b,the observation group was treated with baofukang suppository on the basis of the control group.Clinical efficacy,HPV negative rate,T lymphocyte immune function indexes before and after treatment(CD_(4)^(+) cell fraction,CD_(8)^(+) cell fraction,CD_(4)^(+)/CD_(8)^(+) cell ratio) were compared between the two groups,and the incidence of adverse reactions were observed.Results The total effective rate and HPV negative rate of the observation group were higher than control group(P<0.05).After treatment,the observation group of CD_(4)^(+) cell fraction,CD_(8)^(+)cell fraction and CD_(4)^(+)/CD_(8)^(+) cell ratio were higher than control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Baofukang suppository combined with recombinant human interferonα-2 b have an exact clinical effect for chronic cervicitis complicated with high-risk HPV infection,which can effectively improve the HPV negative rate and immune function of patients,and with high safety.
作者
李海棠
LI Haitang(The Sixth Hospital of Fuzhou,Fuzhou 344000,China)
出处
《临床合理用药杂志》
2021年第6期49-50,53,共3页
Chinese Journal of Clinical Rational Drug Use
